FABP3 and early-onset autosomal dominant Alzheimer disease: In addition, FABP3 has potential as biomarker for disease monitoring: epidemiological studies have shown a close association between elevated levels of FABP3 in sera of patients with Parkinson’s and Alzheimer’s disease and disease progression (Chiasserini et al. 2010; Teunissen et al. 2011).